Nucleoside Reverse Transcriptase Inhibitors
GPTKB entity
Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral drug class
|
| gptkbp:abbreviation |
gptkb:NRTIs
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:category |
antiviral drug
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:discoveredIn |
1980s
|
| gptkbp:example_drug |
gptkb:tenofovir_disoproxil_fumarate
gptkb:didanosine gptkb:stavudine gptkb:abacavir gptkb:lamivudine gptkb:zidovudine gptkb:tenofovir_alafenamide emtricitabine |
| gptkbp:excretion |
kidneys
|
| gptkbp:hasApprovedDrug |
gptkb:zidovudine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nucleoside Reverse Transcriptase Inhibitors
|
| gptkbp:includedIn |
gptkb:HAART
|
| gptkbp:mechanismOfAction |
block viral DNA synthesis
inhibit reverse transcriptase |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
varies by drug
|
| gptkbp:resistantTo |
HIV reverse transcriptase mutations
|
| gptkbp:sideEffect |
gptkb:anemia
peripheral neuropathy lactic acidosis hepatic steatosis |
| gptkbp:target |
gptkb:HIV-1
gptkb:HIV-2 |
| gptkbp:usedFor |
HIV treatment
|
| gptkbp:bfsParent |
gptkb:NRTIs
|
| gptkbp:bfsLayer |
5
|